Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
about
A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancerAntigen-specific active immunotherapy for ovarian cancerHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesTherapeutic cancer vaccines and combination immunotherapies involving vaccinationMinireview: Regulatory T Cells and Ovarian Cancer.The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancerPrimary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.Past, present and future targets for immunotherapy in ovarian cancerImmunotherapy for ovarian cancer.A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?Isolation of dendritic cells from umbilical cord blood using magnetic activated cell sorting or adherence.Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory studyTrial watch: Chemotherapy with immunogenic cell death inducersTherapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.Trial watch: Dendritic cell-based interventions for cancer therapyA Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes.Immunotherapy in ovarian cancer.Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.Opportunities in immunotherapy of ovarian cancer.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.Dendritic cell immunotherapy in ovarian cancer.Chemoimmunotherapy: reengineering tumor immunity.A review of dendritic cell therapy for cancer: progress and challenges.Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.Brain Tumor Immunotherapy: What have We Learned so Far?Immunotherapy in Gynecologic Cancers: Are We There Yet?Cellular immunotherapy of cancer: an overview and future directions.New Approaches for Immune Directed Treatment for Ovarian Cancer.Understanding dendritic cell immunotherapy in ovarian cancer.Effects of sialidase NEU1 siRNA on proliferation, apoptosis, and invasion in human ovarian cancer.Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.Immunological Analysis and Generation of Dendritic Cells From Lavage Fluid Obtained by Cell-Free and Concentrated Ascites Reinfusion Therapy.Cancer Vaccines in Ovarian Cancer: How Can We Improve?
P2860
Q22001066-03801B0D-AEC1-4CB5-B06D-33A7964B465AQ24193567-2D2B3B9F-EA12-4B6D-9DB2-2018C5A97D78Q26822730-E0672498-6C62-4A55-A944-08EDA4257999Q28397609-A41AFC12-E643-42CA-A500-85FDB5E70431Q30244214-5AB04915-444E-4FE1-B7F6-2EED78625159Q33939202-1CB20684-E742-4B34-82CB-5BFE1EA26A8DQ34493886-A9382A2D-7848-494F-AFB1-508A9A98BB05Q35034010-95B2AFA3-37C4-4738-AE1D-B9901D6C3678Q35164189-8588E489-5667-4AB0-A73D-E77EE9352DEBQ35475233-D728D7EA-6769-4D01-91D5-6170E5147A71Q35690280-0DEFA24C-2065-4053-92F1-4D01B7B79B46Q35886589-10877215-409B-4BA7-859D-9BEE74D1E9F9Q36038456-F560DDF4-DBAA-423C-A181-7CDB79E12E48Q36302848-288C845D-08CC-4DFC-89FF-425CACB90259Q36388529-8F9F5D9E-6FCC-4B41-8D14-9182690A6BDCQ36409524-5EDBE774-7788-46D4-BC2A-18EBAC421E00Q36631249-78B0109B-A97E-4C62-B103-11DB2F20E7F1Q36643661-2B3FDBCA-F228-4DDC-8492-CCEC8ED1F849Q36855245-CAA3D239-0050-4729-AB72-1CB21E92C617Q36958112-D987E04C-3D21-47C7-8E61-64831422EC5EQ38002844-E092C889-E538-4128-847C-071101B0665AQ38031280-79E0E2E9-C383-4159-9C34-C2C8870F836AQ38059513-CF0EE31D-4469-43A4-A2AA-2152EF959CF5Q38069183-1CF602DA-8896-4353-98E8-5E803AD71008Q38079749-CD5A4F64-9F62-4691-B4D3-51266923A144Q38099612-788B09EC-D579-406E-BF62-2D4B1A6A3237Q38107203-007AB96C-B0E4-4846-BFB1-FFED42E45126Q38168904-7C31CD72-90EA-4C8A-BA01-96D04B5E2642Q38185156-04B63CD6-BE6C-462C-9E97-493E6D2D0E09Q38542113-14D2E133-3FE0-45EE-BEC4-E757E75E27DDQ38608730-20CBDEF6-D482-4AD5-BDDA-5EA921F81DF1Q38673161-E5732D3E-B7FC-44C3-9C6F-8B35B69858ECQ38760516-B97123CD-05A6-4B1D-8D64-956C86DCD133Q38808249-7A11CD4F-9024-4AF5-BE2C-32E6611BF482Q38828148-6BFF7A73-09C5-462E-9CA9-AEFE8733E046Q39194082-7EEA54F2-7D8F-4FA3-9E41-E83DFCF7C82FQ40127604-55E84AC4-0E1A-490E-9EEE-515E22852E48Q42925679-012627C6-D63E-4143-8A52-E38A1383A5E0Q45869272-C937A7DE-01E4-4138-9F06-568531CA4274Q54385315-329F2D09-68E4-4BB1-83A9-10F5DD453A25
P2860
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Phase I/II randomized trial of ...... in first or second remission.
@en
Phase I/II randomized trial of ...... in first or second remission.
@nl
type
label
Phase I/II randomized trial of ...... in first or second remission.
@en
Phase I/II randomized trial of ...... in first or second remission.
@nl
prefLabel
Phase I/II randomized trial of ...... in first or second remission.
@en
Phase I/II randomized trial of ...... in first or second remission.
@nl
P2093
P2860
P921
P1476
Phase I/II randomized trial of ...... in first or second remission.
@en
P2093
Bruce L Levine
Carl H June
Christina S Chu
Daniel S Schullery
James Bender
Jean Boyer
Mark A Morgan
Phyllis A Gimotty
Robert H Vonderheide
Stephen C Rubin
P2860
P2888
P304
P356
10.1007/S00262-011-1081-8
P577
2011-10-22T00:00:00Z